Browse the corpus

1. Introduction Stroke is the first cause of disability, the second cause of cognitive impairment, and the third cause of death in the world [1]. Two-thirds of all stroke deaths occur in low- and middle-income countries, including Latin America countries; however, stroke has been poorly studied in these regions [2]. In Brazil, the largest country in the region, stroke is the leading cause of death and disability and the stroke mortality is one of the highest among Western countries [3, 4]. The causes of the high stroke burden in Brazil remain speculative. One possibility is that the prevalence of stroke is higher in Brazil than in other regions. Some prevalence studies were carried in Brazil but the data are not sufficient to provide an overview of stroke prevalence in Brazil, since most of these studies were carried out in specific regions that do not necessarily reflect the whole country reality [5]. Other potential explanations rely on medical assistance deficiencies, mostly driven by socioeconomic inequality. In fact, previous studies showed that the majority of patients are assisted in public hospitals where diagnostic and therapeutic resources are scarce [6–9]. However, the negative impact of these discrepancies on stroke outcome in Brazil still requires confirmation by large population studies. At this point few studies have evaluated stroke outcome [7–10] in Brazil and the outcome determinants of stroke in Brazil are still poorly known.

erapeutic resources are scarce [6–9]. However, the negative impact of these discrepancies on stroke outcome in Brazil still requires confirmation by large population studies. At this point few studies have evaluated stroke outcome [7–10] in Brazil and the outcome determinants of stroke in Brazil are still poorly known. Several variables including the higher score with NIH Stroke Scale (NIHSS), higher age, atrial fibrillation, hypertension, diabetes mellitus, lower level of consciousness, higher time between stroke onset and admission, and the presence of visual field abnormalities at the first evaluation have been considered predictors of stroke poor outcome [11–16]. Most of the outcome determinants studies were carried out in developed or Asian countries. The aim of the present study was to evaluate stroke prognosis and stroke prognosis determinants in a population of stroke patients seen in a primary stroke center in São Paulo, the largest Brazilian city. 2. Methods This study was carried out between 2012 and 2014 at Hospital Paulistano, a Joint Commission International certified stroke center located in the central region of São Paulo, Brazil. This study protocol was approved by the Ethics Committee on Research of Hospital Paulistano (Amil Stroke Network) and informed consent was obtained from each participant or legal representative.

ital Paulistano, a Joint Commission International certified stroke center located in the central region of São Paulo, Brazil. This study protocol was approved by the Ethics Committee on Research of Hospital Paulistano (Amil Stroke Network) and informed consent was obtained from each participant or legal representative. 2.1. Patients and Procedures Patients that presented to the emergency room with suspected stroke were evaluated by a neurologist at admission and submitted to a standardized protocol. Demographical data, time delay between stroke onset and admission, stroke warning symptoms (weakness and numbness, confusion, speech difficulties, comprehension problems, vision abnormalities, walking troubles, severe headache, dizziness, and incoordination), and stroke risk factors (hypertension, smoking, contraceptive use, obesity, familial history, diabetes, previous stroke, or transient ischemic attack) were compiled. We also collected the following data at admission: vital signs, capillary glucose, oxygen saturation levels, Glasgow coma scale score, and National Institutes of Health Stroke Scale (NIHSS).

n, smoking, contraceptive use, obesity, familial history, diabetes, previous stroke, or transient ischemic attack) were compiled. We also collected the following data at admission: vital signs, capillary glucose, oxygen saturation levels, Glasgow coma scale score, and National Institutes of Health Stroke Scale (NIHSS). After initial evaluation patients were submitted to noncontrast brain CT with 10-mm slice thickness and radiological findings (detectable brain infarct, dense artery sign, local intracerebral hemorrhage, distant brain hemorrhage, and cerebral edema) were recorded. Patients were diagnosed as having ischemic stroke (IS), transient ischemic attack (TIA), intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SHA) according to previously established definitions [17]. Data of IS treatment including thrombolytic therapy, the use of antithrombotic agents in the first 48 hours, and venous thrombosis prophylaxis were collected. Patients without confirmed stroke and patients with SHA were not included. The outcome determinants analysis was carried exclusively in the groups of patients with confirmed IS or ICH.

cluding thrombolytic therapy, the use of antithrombotic agents in the first 48 hours, and venous thrombosis prophylaxis were collected. Patients without confirmed stroke and patients with SHA were not included. The outcome determinants analysis was carried exclusively in the groups of patients with confirmed IS or ICH. 2.2. Statistical Analysis Statistical analysis was performed using SPSS version 15.0 for Windows. The confidence interval was of 95% and the significance level was set at P < 0.05. Normality was assessed using the Kolmogorov-Smirnov test. Student's t-test was used for continuous data and categorical data were compared using Chi-square analyses. In-hospital mortality and modified Rankin score (mRs) at discharge, whereby the patients were divided into two groups, one with mRs ≤ 2 and other with mRs > 2, were defined as outcomes measures. Binary logistic regression analysis was performed after excluding nonsignificant variables with in-hospital mortality and discharge Rankin modified score as dependent variables. 3. Results Demographic data, stroke risk factors, stroke warning symptoms, and clinical data from the 341 patients included in the study are shown in Table 1.

2.2. Statistical Analysis Statistical analysis was performed using SPSS version 15.0 for Windows. The confidence interval was of 95% and the significance level was set at P < 0.05. Normality was assessed using the Kolmogorov-Smirnov test. Student's t-test was used for continuous data and categorical data were compared using Chi-square analyses. In-hospital mortality and modified Rankin score (mRs) at discharge, whereby the patients were divided into two groups, one with mRs ≤ 2 and other with mRs > 2, were defined as outcomes measures. Binary logistic regression analysis was performed after excluding nonsignificant variables with in-hospital mortality and discharge Rankin modified score as dependent variables. 3. Results Demographic data, stroke risk factors, stroke warning symptoms, and clinical data from the 341 patients included in the study are shown in Table 1. The therapeutic measures adopted in patients with brain ischemia were as follows: twenty-seven out of the 202 patients with IS (13.4% of all IS patients) were treated with thrombolytic treatment, 18 (8.9%) with intravenous and 9 (4.4%) with endovascular therapy. Two hundred fifty-eight out of 303 patients with IS and TIA (85.1%) received antithrombotic therapy within 48 hours after stroke and 93.1% of the group of patients with either IS or TIA received venous thrombosis prophylactic treatment. Among ICH patients, nine (23.7%) were submitted to surgical treatment and the others received conservative treatment.

patients with IS and TIA (85.1%) received antithrombotic therapy within 48 hours after stroke and 93.1% of the group of patients with either IS or TIA received venous thrombosis prophylactic treatment. Among ICH patients, nine (23.7%) were submitted to surgical treatment and the others received conservative treatment. When comparing the clinical features and outcome of patients with IS and ICH, we found that patients with ICH had a more severe disease than patients with IS. Patients with IS had higher diastolic blood pressure (IS: 82 ± 15.6, ICH: 100.9 ± 120, P = 0.011), lower oxygen saturation levels (IS: 96 ± 2.7, ICH: 94.9 ± 4.5, P = 0.038), and lower Glasgow score at admission (IS: 14.3 ± 1.9, ICH: 12.5 ± 3.8, P < 0.001). At discharge patients with ICH had higher NIHSS scores (IS median = 0, interquartile range = 2, ICH median = 2.5, interquartile range = 10, and P < 0.001) and higher mRS (IS median = 0, interquartile range = 2, ICH median = 1.5, interquartile range = 4, and P < 0.001).

sion (IS: 14.3 ± 1.9, ICH: 12.5 ± 3.8, P < 0.001). At discharge patients with ICH had higher NIHSS scores (IS median = 0, interquartile range = 2, ICH median = 2.5, interquartile range = 10, and P < 0.001) and higher mRS (IS median = 0, interquartile range = 2, ICH median = 1.5, interquartile range = 4, and P < 0.001). The outcome measures were evaluated in patients with IS and ICH. Twenty-eight out of 315 patients (8.9%) died during hospitalization, 23 (8.2%) of the patients with IS and 5 (13.9%) of the patients with ICH (P = 0.256). At hospital discharge 31.7% of the survivors had mRs > 2, 28.1% of the IS patients and 62.5% of ICH patients (P < 0.001). Tables 2 and 3 show the comparisons of characteristics of patients according to the outcome measures. After binary regression analysis the only variables significantly associated with mRs > 2 at discharge were ICH diagnosis (P < 0.001), lower oxygen saturation (P = 0.026), lower Glasgow score (P = 0.008), and higher NIHSS at onset (P < 0.001). The only variable associated with in-hospital death was the presence of vision field abnormality at admission (P = 0.018).

ables significantly associated with mRs > 2 at discharge were ICH diagnosis (P < 0.001), lower oxygen saturation (P = 0.026), lower Glasgow score (P = 0.008), and higher NIHSS at onset (P < 0.001). The only variable associated with in-hospital death was the presence of vision field abnormality at admission (P = 0.018). 4. Discussion To our knowledge this was the first study to evaluate outcome determinants in a Brazilian primary stroke center. We found that lower Glasgow score, lower NIHSS, and lower oxygen saturation were independently associated with poorer functional outcome and that visual symptoms at onset were independently associated with in-hospital mortality. These findings are in line with previous studies. NIHSS has been demonstrated as one of the most important outcome predictors among patients with IS [13–16]. Reduced level of consciousness and reduced Glasgow score were found to be associated with poorer outcome in patients with IS [16] and in patients with ICH [18, 19]. Lower oxygen saturation at admission is inversely correlated with stroke prognosis [20]. Visual field abnormalities were associated with unfavorable outcome in patients with IS in a previous study [16]. The association of visual symptoms with poorer outcome could be related with posterior circulation involvement, explaining the worse outcome. Other variables were previously associated with poorer outcome: age, hypertension, diabetes and glucose level at admission, CT hyperdense artery sign, and CT hypointensity [16, 21, 22]. In our study some variables were associated with outcome only by univariate analysis. Patients with poorer functional outcome were of higher age and had higher glucose level, more frequent confusion, vision abnormalities, CT hypodensity, and cerebral edema; however, these differences were not significant after adjusted analysis. CT dense artery sign and cerebral edema were more frequent among those who died during hospitalization; however, these differences were no longer significant after regression analysis. It is possible that the small sample size in the present study did not allow the demonstration of other significant differences.

lysis. CT dense artery sign and cerebral edema were more frequent among those who died during hospitalization; however, these differences were no longer significant after regression analysis. It is possible that the small sample size in the present study did not allow the demonstration of other significant differences. The mean stroke age we found was similar to what was found in a recent study in United States [23]. ICH proportion and ICH severity were similar to previous descriptions [24]. The therapeutic measures registered here are in accordance with stroke care quality indicators. The percentage of IS patients treated with tPA in our study was even higher than in previous population studies [25], probably reflecting the fact that our study was carried in a single institution with 24-hour neurologist and a stroke protocol. The rate of patients that received antithrombotic therapy within the first 48 hours after stroke (85.1%) and the rate of patients submitted to venous thrombosis prophylactic treatment (93.1%) are similar to what was previously reported in US hospitals [26, 27] and in other private hospitals in Brazil [28]. The in-hospital mortality rate registered here was not discrepant from previous studies in developed countries [29]. Overall these data suggest that the clinical, therapeutic, and outcome characteristics of the population of the present study do not remarkably differ from stroke populations in developed countries. It is likely that this reflects the fact that the present study was carried out in a private institution, with availability of all stroke validated therapies. Our hospital serves predominantly middle and upper middle class patients. The emergence service of our hospital has a neurologist 24 hours a day, 7 days a week, a nurse in charge of the management of stroke cases, intensive care unit, 24-hour CT scan, magnetic resonance imaging, and an interventional neuroradiology service available 24 hours a day, 7 days a week. It is a primary stroke center certified by Joint Commission International that follows the American Heart Association guidelines. Considering the specificities of our service, large and multicentric studies are still needed to determine if the outcome of stroke among patients assisted in public Brazilian hospitals differs from private hospitals.

er certified by Joint Commission International that follows the American Heart Association guidelines. Considering the specificities of our service, large and multicentric studies are still needed to determine if the outcome of stroke among patients assisted in public Brazilian hospitals differs from private hospitals. Our study has some limitations that deserve to be mentioned. We analyzed a small and a single center sample. Our results need confirmation in larger and multicentric studies involving different Brazilian regions with different socioeconomic levels. Another limitation is that this study did not include follow-up of the patients and we evaluated only in-hospital outcomes, while most of the prognostic studies assess three-month outcome. Future outcome studies should address long-term outcome in patients with stroke in Brazil. As strengths of this study the population was homogeneous and the same stroke team assisted all the patients following the same stroke protocols. In conclusion, the present study was the first to specifically assess outcome determinants in a Brazilian primary stroke center with availability of all current validated stroke therapies. The outcome and outcome determinants reported in the present study shared great similarities with previous studies in developed countries. Population studies are still necessary to better understand the great burden of stroke in Brazil. Disclosure Dr. Renan B. Domingues is a recipient of a CAPES postdoctoral scholarship.

In conclusion, the present study was the first to specifically assess outcome determinants in a Brazilian primary stroke center with availability of all current validated stroke therapies. The outcome and outcome determinants reported in the present study shared great similarities with previous studies in developed countries. Population studies are still necessary to better understand the great burden of stroke in Brazil. Disclosure Dr. Renan B. Domingues is a recipient of a CAPES postdoctoral scholarship. Conflict of Interests The authors declare that there is no conflict of interests regarding the publication of this paper. Table 1 Demographical, clinical, and radiological data of the 341 patients included in the study.

In conclusion, the present study was the first to specifically assess outcome determinants in a Brazilian primary stroke center with availability of all current validated stroke therapies. The outcome and outcome determinants reported in the present study shared great similarities with previous studies in developed countries. Population studies are still necessary to better understand the great burden of stroke in Brazil. Disclosure Dr. Renan B. Domingues is a recipient of a CAPES postdoctoral scholarship. Conflict of Interests The authors declare that there is no conflict of interests regarding the publication of this paper. Table 1 Demographical, clinical, and radiological data of the 341 patients included in the study. Characteristics Findings Age (mean ± SD) 66.8 ± 15.7 years Gender Male (%) 52.2 Female (%) 47.8 Type of stroke IS (%) 59.2 TIA (%) 29.6 ICH (%) 11.1 Previous hypertension (%) 68 Diabetes (%) 37 Previous stroke (%) 26.4 Smoking (%) 14 Obesity (%) 7.9 Familial history of stroke (%) 7 Time of symptoms at arrival* (mean ± SD) 1661 ± 3979 minutes Wake-up stroke (%)* 25.2 Stroke warning symptoms* Weakness and numbness (%) 66.6 Confusion, speech difficulties, and comprehension problems (%) 39 Dizziness and incoordination (%) 19.6 Severe headache (%) 16.7 Walking troubles (%) 16.4 Vision abnormalities (%) 11.1 Systolic blood pressure (mean ± SD)* 148.9 ± 54.1 mm Hg Diastolic blood pressure (mean ± SD)* 84.1 ± 42.8 mm Hg Heart rate (mean ± SD)* 80.8 ± 15.9 beats per minute Oxygen saturation level (mean ± SD)* 95.9 ± 3% Capillary glycemia (mean ± SD)* 137.1 ± 56.1 mg/dL Temperature (mean ± SD)* 35.9 ± 2.9 Celsius Glasgow score (mean ± SD)* 14.1 ± 2.3 NIHSS at admission* Median = 2, interquartile range = 5 NIHSS at discharge** Median = 0, interquartile range = 2 *Data obtained at the first evaluation; **data obtained at discharge; IS: ischemic stroke; ICH: intracerebral hemorrhage; TIA: transient ischemic attack; NIHSS: National Institutes of Health Stroke Scale.

.3 NIHSS at admission* Median = 2, interquartile range = 5 NIHSS at discharge** Median = 0, interquartile range = 2 *Data obtained at the first evaluation; **data obtained at discharge; IS: ischemic stroke; ICH: intracerebral hemorrhage; TIA: transient ischemic attack; NIHSS: National Institutes of Health Stroke Scale. Table 2 Comparison of clinical and radiological data according to the modified Rankin score (mRs) at discharge. mRs ≤ 2 (N = 157) mRs > 2 (N = 73) P P * Age 65.1 ± 15.5 72.2 ± 15 <0.001 0.398 Male 90 (39.1%) 36 (15.7%) 0.256 — Smoking 25 (10.1%) 9 (3.9%) 0.463 — Hypertension 105 (45.7%) 58 (25.2%) 0.061 — Obesity 15 (6.5%) 7 (3%) 0.993 — Family history 12 (5.2%) 4 (1.7%) 0.548 — Diabetes 60 (26.1%) 29 (12.6%) 0.827 — Previous stroke 42 (18.3%) 19 (8.3%) 0.908 — Weakness and numbness 109 (47.4%) 54 (23.5%) 0.307 — Confusion, speech difficulties, and comprehension problems 53 (23%) 38 (16.5%) 0.017 0.130 Vision abnormalities 24 (10.4%) 2 (0.9%) 0.012 0.998 Walking troubles 22 (9.5%) 18 (7.8%) 0.071 — Severe headache 27 (11.7%) 7 (3%) 0.147 — Dizziness and incoordination 33 (14.3%) 11 (4.8%) 0.239 — CT detectable brain infarct 25 (10.9%) 20 (8.7%) 0.035 0.778 CT dense artery sign 3 (1.3%) 7 (3%) 0.073 — Cerebral edema 4 (1.7%) 11 (4.8%) 0.004 1.000 Wake-up stroke 35 (15.2%) 26 (11.3%) 0.068 — SBP 147.3 ± 25.8 147.2 ± 29.5 0.973 — DBP 86.8 ± 60.4 84.5 ± 15 0.745 — HR 80.4 ± 15.5 81.8 ± 19.3 0.563 — Sat O2 96.5 ± 2.1 94.4 ± 4.5 <0.001 0.026

Age 65.1 ± 15.5 72.2 ± 15 <0.001 0.398 Male 90 (39.1%) 36 (15.7%) 0.256 — Smoking 25 (10.1%) 9 (3.9%) 0.463 — Hypertension 105 (45.7%) 58 (25.2%) 0.061 — Obesity 15 (6.5%) 7 (3%) 0.993 — Family history 12 (5.2%) 4 (1.7%) 0.548 — Diabetes 60 (26.1%) 29 (12.6%) 0.827 — Previous stroke 42 (18.3%) 19 (8.3%) 0.908 — Weakness and numbness 109 (47.4%) 54 (23.5%) 0.307 — Confusion, speech difficulties, and comprehension problems 53 (23%) 38 (16.5%) 0.017 0.130 Vision abnormalities 24 (10.4%) 2 (0.9%) 0.012 0.998 Walking troubles 22 (9.5%) 18 (7.8%) 0.071 — Severe headache 27 (11.7%) 7 (3%) 0.147 — Dizziness and incoordination 33 (14.3%) 11 (4.8%) 0.239 — CT detectable brain infarct 25 (10.9%) 20 (8.7%) 0.035 0.778 CT dense artery sign 3 (1.3%) 7 (3%) 0.073 — Cerebral edema 4 (1.7%) 11 (4.8%) 0.004 1.000 Wake-up stroke 35 (15.2%) 26 (11.3%) 0.068 — SBP 147.3 ± 25.8 147.2 ± 29.5 0.973 — DBP 86.8 ± 60.4 84.5 ± 15 0.745 — HR 80.4 ± 15.5 81.8 ± 19.3 0.563 — Sat O2 96.5 ± 2.1 94.4 ± 4.5 <0.001 0.026 Temperature 35.9 ± 2.9 35.6 ± 4.4 0.555 — Digital glycemia 130.8 ± 50.1 148.7 ± 62 0.040 0.846 Time of symptoms 1359.6 ± 2697 1850.8 ± 4091.4 0.330 — Glasgow (initial) 14.7 ± 1.4 13.1 ± 3.2 <0.001 0.008 NIHSS (initial) Median = 1, IR = 3 Median = 12, IR = 14 <0.001 <0.001

Age 65.1 ± 15.5 72.2 ± 15 <0.001 0.398 Male 90 (39.1%) 36 (15.7%) 0.256 — Smoking 25 (10.1%) 9 (3.9%) 0.463 — Hypertension 105 (45.7%) 58 (25.2%) 0.061 — Obesity 15 (6.5%) 7 (3%) 0.993 — Family history 12 (5.2%) 4 (1.7%) 0.548 — Diabetes 60 (26.1%) 29 (12.6%) 0.827 — Previous stroke 42 (18.3%) 19 (8.3%) 0.908 — Weakness and numbness 109 (47.4%) 54 (23.5%) 0.307 — Confusion, speech difficulties, and comprehension problems 53 (23%) 38 (16.5%) 0.017 0.130 Vision abnormalities 24 (10.4%) 2 (0.9%) 0.012 0.998 Walking troubles 22 (9.5%) 18 (7.8%) 0.071 — Severe headache 27 (11.7%) 7 (3%) 0.147 — Dizziness and incoordination 33 (14.3%) 11 (4.8%) 0.239 — CT detectable brain infarct 25 (10.9%) 20 (8.7%) 0.035 0.778 CT dense artery sign 3 (1.3%) 7 (3%) 0.073 — Cerebral edema 4 (1.7%) 11 (4.8%) 0.004 1.000 Wake-up stroke 35 (15.2%) 26 (11.3%) 0.068 — SBP 147.3 ± 25.8 147.2 ± 29.5 0.973 — DBP 86.8 ± 60.4 84.5 ± 15 0.745 — HR 80.4 ± 15.5 81.8 ± 19.3 0.563 — Sat O2 96.5 ± 2.1 94.4 ± 4.5 <0.001 0.026 Temperature 35.9 ± 2.9 35.6 ± 4.4 0.555 — Digital glycemia 130.8 ± 50.1 148.7 ± 62 0.040 0.846 Time of symptoms 1359.6 ± 2697 1850.8 ± 4091.4 0.330 — Glasgow (initial) 14.7 ± 1.4 13.1 ± 3.2 <0.001 0.008 NIHSS (initial) Median = 1, IR = 3 Median = 12, IR = 14 <0.001 <0.001 CT: computed tomography; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; Sat O2: oxygen saturation; NIHSS: National Institutes of Health Stroke Scale; IR = interquartile range; P: according to t-test (continuous variables) or Chi-square test (categorical variables); P*: according to binary logistic regression analysis with significant variables.

BP: diastolic blood pressure; HR: heart rate; Sat O2: oxygen saturation; NIHSS: National Institutes of Health Stroke Scale; IR = interquartile range; P: according to t-test (continuous variables) or Chi-square test (categorical variables); P*: according to binary logistic regression analysis with significant variables. Table 3 Comparison of clinical and radiological data of survivors and patients that died during hospitalization. Survivors (N = 287) In-hospital death (N = 28) P P * Age 66.4 ± 15.8 68.5 ± 16.7 0.509 — Male 156 (49.5%) 15 (4.8%) 0.555 — Smoking 44 (14%) 4 (1.3%) 0.904 — Hypertension 194 (61.6%) 22 (7%) 0.361 — Obesity 23 (7.3%) 4 (12.7%) 0.498 — Family history 20 (6.3%) 2 (0.6%) 0.001 — Diabetes 107 (34%) 9 (2.8%) 0.652 — Previous stroke 75 (23.8%) 9 (2.8%) 0.189 — Weakness and numbness 192 (60.9%) 19 (6%) 0.179 — Confusion, speech difficulties, and comprehension problems 111 (35.2%) 10 (3.2%) 0.121 — Vision abnormalities 27 (8.6%) 7 (2.2%) 0.024 0.018

Age 66.4 ± 15.8 68.5 ± 16.7 0.509 — Male 156 (49.5%) 15 (4.8%) 0.555 — Smoking 44 (14%) 4 (1.3%) 0.904 — Hypertension 194 (61.6%) 22 (7%) 0.361 — Obesity 23 (7.3%) 4 (12.7%) 0.498 — Family history 20 (6.3%) 2 (0.6%) 0.001 — Diabetes 107 (34%) 9 (2.8%) 0.652 — Previous stroke 75 (23.8%) 9 (2.8%) 0.189 — Weakness and numbness 192 (60.9%) 19 (6%) 0.179 — Confusion, speech difficulties, and comprehension problems 111 (35.2%) 10 (3.2%) 0.121 — Vision abnormalities 27 (8.6%) 7 (2.2%) 0.024 0.018 Walking troubles 47 (14.9%) 5 (1.6%) 0.072 — Severe headache 48 (15.2%) 7 (2.2%) 0.135 — Dizziness and incoordination 60 (19%) 5 (15.9%) 0.064 — CT detectable brain infarct 56 (17.8%) 7 (2.2%) 0.538 — CT dense artery sign 13 (4.1%) 3 (0.9%) 0.005 0.599 Cerebral edema 18 (5.7%) 2 (0.6%) 0.002 1.000 Wake-up stroke 78 (24.8%) 4 (1.3%) 0.282 — SBP 150.2 ± 58 142.1 ± 24.7 0.165 — DBP 84.8 ± 46.2 81.8 ± 15.6 0.463 — HR 80.7 ± 15.8 78.2 ± 19.5 0.516 — Sat O2 95.8 ± 3.2 96.5 ± 2.4 0.180 — Temperature 35.9 ± 3.1 36 ± 0.4 0.460 — Digital glycemia 136.6 ± 55 122 ± 33.9 0.100 — Time of symptoms 1777.7 ± 4215.2 773.25 ± 1180.7 0.009 0.252 Glasgow (initial) 5.4 ± 7.5 6 ± 7.6 0.685 0.293 NIHSS (initial) Median = 2, IR = 8 Median = 2, IR = 10 0.694 0.125 CT: computed tomography; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; Sat O2: oxygen saturation; NIHSS: National Institutes of Health Stroke Scale; IR = interquartile range; P: according to t-test (continuous variables) or Chi-square test (categorical variables); P*: according to binary logistic regression analysis with significant variables.